Physician profile
Ryan E Waugh
NPI 1992319248
$4,425.03
in general payments reported to CMS, 2019-2025
34 companies · $2,507 in 2025
The $2,507 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $448 · 2022: $138 · 2023: $161 · 2024: $1,172 · 2025: $2,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,719 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.67 |
| Education | $120.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $747.05 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $418.56 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $365.32 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $345.90 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $294.30 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $291.38 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $272.10 | 2024-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $248.69 | 2024-2025 | Ingrezza |
| Abbvie INC. | $175.96 | 2024-2025 | |
| Lundbeck LLC | $172.05 | 2024-2025 | Rexulti |
| Biogen, INC. | $142.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.37 | 2021-2025 | Trintellix, Vpriv |
| Astrazeneca Pharmaceuticals LP | $121.73 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $94.76 | 2021-2024 | Mounjaro, Zepbound |
| Urovant Sciences INC | $77.91 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $49.99 | 2024-2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $48.31 | 2023-2024 | |
| Novo Nordisk INC | $48.26 | 2021-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.91 | 2021-2022 | |
| Astellas Pharma US INC | $35.14 | 2021 | |
| Corcept Therapeutics | $32.40 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $31.82 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $30.11 | 2021 | |
| Sunovion Pharmaceuticals INC. | $29.35 | 2021 | |
| Avanir Pharmaceuticals, INC. | $27.13 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $20.86 | 2023 | Seglentis |
| Ucb, INC. | $20.14 | 2021 | |
| Boston Scientific Corporation | $19.46 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.92 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $16.15 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $14.73 | 2025 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.48 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $13.58 | 2021 | |
| Janssen Scientific Affairs, LLC | $13.16 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Waugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.